Novel aminobenzimidazoles as selective MCH-R1 antagonists for the treatment of metabolic diseases

A series of novel aminobenzimidazoles was prepared and evaluated for h-MCH-R1 antagonist properties. Most of the compounds showed excellent h-MCH-R1 binding affinity as well as mouse ex vivo binding. Compounds 9 and 18 were active in mouse DIO studies at 30 mpk.

A series of potent and highly selective melanin-concentrating hormone (MCH) inhibitors is described.Figure optionsDownload as PowerPoint slide